Potential Role of Histone Deacetylase Inhibitors in Mesothelioma: Clinical Experience with Suberoylanilide Hydroxamic Acid
- 1 January 2006
- journal article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 7 (4), 257-261
- https://doi.org/10.3816/clc.2006.n.003
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- An Overview of Chemotherapy for MesotheliomaHematology/Oncology Clinics of North America, 2005
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group BClinical Cancer Research, 2005
- Histone Deacetylase InhibitorsAdvances in Cancer Research, 2004
- Mesothelioma Trends in the United States: An Update Based on Surveillance, Epidemiology, and End Results Program Data for 1973 through 2003American Journal of Epidemiology, 2004
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Combination of Raltitrexed and Oxaliplatin Is an Active Regimen in Malignant Mesothelioma: Results of a Phase II StudyJournal of Clinical Oncology, 2003
- Phase II trial of ZD0473 as second-line therapy in mesotheliomaEuropean Journal Of Cancer, 2002
- Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase in Patients With Unresectable Malignant MesotheliomaJournal of Clinical Oncology, 2002
- Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibodyBritish Journal of Cancer, 1990